Jacobs Levy Equity Management’s Lisata Therapeutics LSTA Stock Holding History

Jacobs Levy Equity Management’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,325	Closed	-$226K	–	1039
2018 Q2	$226K	Sell	2,325 -100	-4%	-$7.05K	﹤0.01%	934
2018 Q1	$212K	Sell	2,425 -87	-3%	-$6.03K	﹤0.01%	918
2017 Q4	$132K	Hold	2,512	–	–	﹤0.01%	942
2017 Q3	$135K	Buy	2,512 +986	+65%	+$59.9K	﹤0.01%	906
2017 Q2	$106K	Buy	1,526 +325	+27%	+$23K	﹤0.01%	893
2017 Q1	$91K	Sell	1,201 -193	-14%	-$13.4K	﹤0.01%	866
2016 Q4	$59K	Hold	1,394	–	–	﹤0.01%	931
2016 Q3	$97K	Sell	1,394 -12	-0.9%	-$967	﹤0.01%	965
2016 Q2	$124K	Buy	1,406 +301	+27%	+$27.7K	﹤0.01%	1070
2016 Q1	$124K	Buy	+1,105	New	+$109K	﹤0.01%	1018
2015 Q2	–	Sell	-299	Closed	-$114K	–	835
2015 Q1	$114K	Buy	+299	New	+$162K	﹤0.01%	741

Other funds holding LSTA

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

TFO

Tarbox Family Office Newport Beach, California $698M AUM 23.16% 1-Year Est. Return

Jacobs Levy Equity Management's LSTA Position: Q3 2018 in Review

Jacobs Levy Equity Management sold out of Lisata Therapeutics (LSTA) in Q3 2018, closing a stake of 2,325 shares — an estimated $226K sold.

Jacobs Levy Equity Management first reported a position in LSTA in Q1 2015 and held it in 11 quarters. The position peaked at $226K in Q2 2018. 29 funds tracked by Wall St. Rank hold LSTA as of Q3 2018.

Jacobs Levy Equity Management reported no remaining Lisata Therapeutics position as of Q3 2018 after selling out during the quarter.
Jacobs Levy Equity Management sold 2,325 Lisata Therapeutics shares in Q3 2018, an estimated $226K.
Jacobs Levy Equity Management first reported a position in Lisata Therapeutics in Q1 2015 and held it in 11 quarters.
Jacobs Levy Equity Management's Lisata Therapeutics position peaked at $226K in Q2 2018.
29 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.